Zoetis Inc.

Zoetis Inc. is the world's largest animal health company, discovering, developing, manufacturing, and commercializing medicines, vaccines, diagnostics, and biodevices across eight core species — companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish, sheep) — with $9.47 billion in revenue in fiscal 2025. Spun off from Pfizer in 2013, the company has built the industry's broadest portfolio, anchored by blockbuster franchises in parasiticides (Simparica/Simparica Trio), dermatology (Apoquel, Cytopoint), and osteoarthritis pain (Librela, Solensia), and has delivered a decade of mid-to-high single-digit organic revenue growth with gross margins above 70% that any human pharma company would envy.

This is a story about a dominant incumbent navigating the gap between innovation cycles. Zoetis' companion animal portfolio — roughly 70% of revenue and nearly all the growth — is facing a convergence of pressures: a multiyear cumulative price burden on pet owners that has suppressed clinic visits, an increasingly crowded competitive field in dermatology and parasiticides where price-based competition is displacing the market-expansion dynamics that historically cushioned new entrants, and a pipeline whose next wave of blockbusters is expected to begin contributing meaningfully in late 2027 and into 2028. The stock has fallen roughly 55% from its 2025 highs, repricing the company from a premium compounder to something closer to a challenged incumbent. The file turns on a single question: whether Zoetis' innovation engine and market position are strong enough to bridge the next 18-24 months without permanent impairment to its competitive standing.